换一批
换一批Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
作者：
Andrew R,Clamp [1]
;
Domenica,Lorusso [2]
;
Amit M,Oza [3]
;
Carol,Aghajanian [4]
;
Ana,Oaknin [5]
;
Andrew,Dean [6]
;
Nicoletta,Colombo [7]
;
Johanne I,Weberpals [8]
;
Giovanni,Scambia [9]
;
Alexandra,Leary [10]
;
Robert W,Holloway [11]
;
Margarita,Amenedo Gancedo [12]
;
Peter C,Fong [13]
;
Jeffrey C,Goh [14]
;
David M,O'Malley [15]
;
Deborah K,Armstrong [16]
;
Susana,Banerjee [17]
;
Jesus,García-Donas [18]
;
Elizabeth M,Swisher [19]
;
Terri,Cameron [20]
;
Sandra,Goble [21]
;
Robert L,Coleman [22]
;
Jonathan A,Ledermann [23]
作者单位：
Department of Medical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
[1]
Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies and Gynecologic Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy domenica.lorusso@policlinicogemelli.it.
[2]
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
[3]
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
[4]
Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
[5]
Department of Oncology, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia.
[6]
Gynecologic Cancer Program, University of Milan-Bicocca and European Institute of Oncology (IEO) IRCCS, Milan, Italy.
[7]
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
[8]
Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS and Scientific Directorate, Rome, Italy.
[9]
Gynecological Unit, Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif, France.
[10]
Department of Gynecologic Oncology, Florida Hospital Cancer Institute, Orlando, Florida, USA.
[11]
Medical Oncology Department, Oncology Center of Galicia, La Coruña, Spain.
[12]
Medical Oncology Department, Auckland City Hospital and University of Auckland, Auckland, New Zealand.
[13]
Department of Oncology, Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
[14]
University of Queensland, St Lucia, Queensland, Australia.
[15]
Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, Ohio, USA.
[16]
Oncology, Gynecology and Obstetrics, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA.
[17]
Gynecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
[18]
Division of Medical Oncology, HM Hospitales-Centro Integral Oncológico Hospital de Madrid Clara Campal, Madrid, Spain.
[19]
Division of Gynecologic Oncology, University of Washington, Seattle, Washington, USA.
[20]
Clinical Science, Clovis Oncology UK Ltd, Cambridge, UK.
[21]
Biostatistics, Clovis Oncology, Inc, Boulder, Colorado, USA.
[22]
Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
[23]
Department of Oncology, UCL Cancer Institute, University College London and UCL Hospitals, London, UK.
[24]
关键词
ovarian cancer
主题词
双盲法(Double-Blind Method);女(雌)性(Female);人类(Humans);吲哚类(Indoles);肿瘤复发, 局部(Neoplasm Recurrence, Local)
DOI
10.1136/ijgc-2020-002240
PMID
34103386
发布时间
2022-09-07
- 浏览0
International journal of gynecological cancer
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
